Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00154427 · ClinicalTrials.gov registry record · Phase 2
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT00154427 is a Phase 2 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 172 participants.
The verdict
NCT00154427, a Phase 2 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA). The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of post-operative bleeding in patients following cardiac surgery.
Interventions
- DRUG activated recombinant human factor VII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00154427
The ClinicalTrials.gov registry entry for NCT00154427 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which activated recombinant human factor VII is the first listed.
NCT00154427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00154427 about?
NCT00154427 is a clinical study titled "Use of Activated Recombinant Human Factor VII in Cardiac Surgery". This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA). The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of post-operative bleeding in patients following cardiac surgery.
What is the current status of trial NCT00154427?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2004-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00154427?
The interventions under investigation include: activated recombinant human factor VII (DRUG).
Who is sponsoring clinical trial NCT00154427?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.